2024 World Conference on Lung Cancer (WCLC) - Posters-P3.06E.01 Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS)

Pdf Summary

The document discusses two studies focusing on the clinical and genomic profiles of non-small cell lung cancer (NSCLC) among different ethnic groups, highlighting significant disparities in treatment outcomes and genomic features. <br /><br />The first study investigates socioeconomic and overall survival disparities among ethnic-minority patients (Hispanics, Non-Hispanic Blacks, and Asians) with EGFR-mutated NSCLC treated with Osimertinib at Montefiore’s Cancer Center. Despite similar adherence to treatment, Non-Hispanic Blacks had notably inferior survival outcomes compared to Non-Hispanic Whites. Socioeconomic factors such as income and insurance coverage were linked with survival disparities. The study calls for further research to bridge clinical outcome disparities and highlights pharmacogenetic differences, such as CYP3A4/5 metabolism rates that may affect drug efficacy in different ethnic groups.<br /><br />The second study evaluates genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS), emphasizing on actionable mutational changes and immune landscape differences. LUAS, an uncommon NSCLC histology, showed significant genomic alterations with a higher frequency of MET mutations compared to other lung cancer types. The immune composition of LUAS tumors reveals elevated expressions of PD-L1 and immune infiltrates like CD8 T cells. Although overall survival differed in LUAS compared to squamous cell carcinoma (SCC), it paralleled that of adenocarcinoma (AC) when stratified by PD-L1 expression. There was no notable difference in overall survival when LUAS were treated with immunotherapy, chemotherapy, or targeted TKI agents.<br /><br />Both studies underscore the need for comprehensive approaches to understand the impact of molecular and social determinants on treatment outcomes and highlight potential areas for targeted research and intervention, including the exploration of MET mutations and immune landscape components in LUAS, and stratified pharmacogenomic studies among minority groups receiving NSCLC therapies.

Asset Subtitle

Matthew Lee

Meta Tag

Speaker Matthew Lee

Topic Pathology & Biomarkers

Keywords

non-small cell lung cancer

NSCLC

ethnic disparities

EGFR mutations

Osimertinib

socioeconomic factors

pharmacogenetics

LUAS

MET mutations

immune landscape